Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults

Journal of Infectious Diseases

Volumn 190, Issue 4, 2004, Pages 702-706

  Nitayaphan, Sorachai ^a,f   Pitisuttithum, Punnee ^a   Karnasuta, Chitraporn ^a   Eamsila, Chirapa ^a   De Souza, Mark ^a   Morgan, Patricia ^a   Polonis, Victoria ^a,c   Benenson, Michael ^a   VanCott, Tom ^c   Ratto Kim, Silvia ^a,g   Kim, Jerome ^c,h   Thapinta, Darawan ^b   Garner, Robin ^c   Bussaratid, Valai ^a   Singharaj, Pricha ^a   El Habib, Raphaelle ^d   Gurunathan, Sanjay ^d   Heyward, William ^e   Birx, Deborah ^c   McNeil, John ^c,i   Brown, Arthur E ^a   more..

^a MAHIDOL UNIVERSITY   (Thailand)

^b CHIANG MAI UNIVERSITY   (Thailand)

^c WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^d SANOFI PASTEUR   (France)

^e VaxGen Inc   (United States)

^f ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES   (Thailand)

^g Leahi Hospital   (United States)

^h TRIPLER ARMY MEDICAL CENTER   (United States)

ⁱ NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AIDSVAX B; AIDSVAX E; ALVAC HIV; CD8 ANTIGEN; GLYCOPROTEIN E; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY; PROTEIN ANTIBODY; VCP 1521;

ADULT; ANTIBODY RESPONSE; ANTIGEN BINDING; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DOUBLE BLIND PROCEDURE; ERYTHEMA; FEMALE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MALE; MYALGIA; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; THAILAND;

ADULT; AIDS VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV SERONEGATIVITY; HUMANS; IMMUNIZATION SCHEDULE; IMMUNIZATION, SECONDARY; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; NEUTRALIZATION TESTS; THAILAND; TIME FACTORS; VACCINATION;

EID: 20244383550     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/422258     Document Type: Article

References (14)

1. Mason CJ, Kitsiripornchai S, Markowitz LE, et al. Nationwide surveillance of HIV-1 prevalence and subtype in young Thai men. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 19:165-73.
2. Torugsa K, Anderson S, Thongsen N, et al. HIV epidemic among young Thai men, 1991-2000. Emerg Infect Dis 2003; 9:881-3.
3. VanCott TC, Mascola JR, Kaminski RW, et al. Antibodies with specificity to native gp120 and neutralization activity against primary HIV-1 isolates elicited by immunization with oligomeric gp160. J Virol 1997; 71:4319-30.
4. Kim JH, Pitisuttithum P, Kamboonruang C, et al. Specific antibody responses to vaccination with bivalent CM235/SF2 gp120: detection of homologous and heterologous neutralizing antibody to subtype E (CRF01_AE) HIV type 1. AIDS Res Hum Retroviruses 2003; 19:807-16.
5. Pitisuttithum P, Nitayaphan S, Thongcharoen P, et al. Safety and immunogenicity of combinations of recombinant subtype E and B human immunodeficiency virus type 1 envelope glycoprotein 120 vaccines in healthy Thai adults. J Infect Dis 2003; 188:219-27.
6. Mascola JR. Neutralization of HIV-1 infection of human peripheral blood mononuclear cells (PBMC): antibody dilution method. In: Michael NL, Kim JH, eds. HIV protocols. Vol. 17. Totowa, NJ: Humana Press, 1999:309-15.
7. Lynch JA, de Souza M, Robb MD, et al. Cross-clade cytotoxic T cell response to human immunodeficiency virus type 1 proteins among HLA disparate North Americans and Thais. J Infect Dis 1998; 178:1040-6.
8. Nitayaphan S, Khamboonruang C, Sirisophana N, et al. A phase I/II trial of HIV SF2 gp120/MF59 vaccine in seronegative Thais. Vaccine 2000; 18:1448-55.
9. Belshe RB, Stevens C, Gorse GJ, et al. Safety and immunogenicity of canarypox-vectored human immunodeficiency virus type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers. J Infect Dis 2001; 183:1343-52.
10. Gupta K, Hudgens M, Corey L, et al. Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS Vaccine Evaluation Group Protocol 022A. J Acquir Immune Defic Syndr 2002; 29:254-61.
11. Cao H, Kaleebu P, Hom D, et al. Immunogenicity of a recombinant human immunodeficiency virus (HIV)-canarypox vaccine in HIV-seronegative Ugandan volunteers: results of the HIV Network for Prevention Trials 007 vaccine study. J Infect Dis 2003; 187:887-95.
12. Belshe RB, Gorse GJ, Mulligan MJ, et al. Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. AIDS 1998; 12:2407-15.
13. + cytotoxic T lymphocyte responses in seronegative volunteers. J Infect Dis 1999; 180:290-8.
14. AIDS Vaccine Evaluation Group 022 Protocol Team. Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 Env, Gag, and Pro in combination with rgp120. J Infect Dis 2001; 183:563-70.